Posted on

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

 Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system

Go to Source

By sf-admin